Mode
Text Size
Log in / Sign up

Once-weekly basal insulin improves HbA1c by 0.09% and time in range over daily regimensWeekly insulin offers easier management for people with type 2 diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that once-weekly basal insulin provides comparable safety and modest improvements in glycemic control over daily regimens.

This meta-analysis synthesized data from 14 randomized controlled trials involving 8,487 subjects with type 2 diabetes to compare once-weekly basal insulin analogs against daily basal insulin regimens. The analysis focused on primary outcomes of glycemic control and secondary outcomes including time in range (TIR) and the likelihood of achieving an HbA1c < 7.0%.

The meta-analysis found that once-weekly basal insulin resulted in a greater reduction in HbA1c by -0.09% (95% CI -0.15 to -0.03) compared to daily regimens. Additionally, patients on once-weekly regimens showed greater improvements in time in range of 1.86% (95% CI 0.73 to 2.98). There were also higher odds of attaining an HbA1c < 7.0% with a reported effect size of 1.32 (95% CI 1.07 to 1.63, I2 64.9%).

Regarding safety, the rates of level 2 or 3 hypoglycemia did not differ significantly between the two groups, suggesting a similar safety profile. The primary clinical advantage identified is treatment simplification and reduced injection burden for patients with type 2 diabetes. While results favor once-weekly regimens for convenience and modest glycemic improvements, these findings should be integrated into clinical practice as part of a personalized management plan.

How this fits prior evidence

This meta-analysis addresses a gap in evidence regarding the efficacy of simplified dosing schedules for type 2 diabetes. It provides data on once-weekly basal insulin, which offers an alternative to daily regimens. While other covered findings discuss SGLT2 inhibitors and semaglutide for mortality or kidney protection, this study specifically focuses on the impact of injection frequency on HbA1c and time in range.

Managing type 2 diabetes often requires a strict daily routine of insulin injections. For many people, this constant schedule can feel like a heavy burden. New data from a large review of clinical trials suggests that switching to a once-weekly insulin dose might simplify life without sacrificing health goals.

The study looked at over 8,000 adults with type 2 diabetes. It compared weekly insulin to the standard daily injections. The results showed that people on the weekly schedule had slightly better blood sugar control and more time spent in a healthy range. They also had better odds of reaching a specific target for their average blood sugar levels.

Safety is a major concern when changing insulin routines. This review found that the risk of low blood sugar, known as hypoglycemia, was similar for both the weekly and daily versions. While the improvements in blood sugar numbers were modest, the main benefit for patients is the much simpler schedule. Talk to your doctor to see if this simplified routine is right for your specific needs.

What this means for you:
Weekly insulin provides similar safety and slightly better blood sugar control than daily shots for type 2 diabetes.

Common questions

Is it safe to switch from daily to weekly insulin?

The study found that the risk of low blood sugar, known as level 2 or 3 hypoglycemia, did not differ significantly between those taking weekly and daily insulin. The safety profile was similar for both regimens, making it a potentially safer alternative for simplifying your treatment routine.

How does weekly insulin compare to daily shots for blood sugar?

Patients on once-weekly insulin showed slightly better results than those on daily insulin. This included a greater reduction in HbA1c (the average blood sugar over months) and more time spent in the target range. There were also higher odds of reaching an HbA1c goal of less than 7.0%.

Who is this new insulin option for?

This finding applies to adults with type 2 diabetes. The main advantage of the weekly version is that it simplifies treatment and reduces the number of injections a person must give themselves each week while maintaining effective control.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
PURPOSE OF REVIEW: Recently developed once-weekly basal insulin analogs, including insulin icodec and insulin efsitora alpha (efsitora), aim to improve treatment adherence and patient convenience compared with daily basal insulin. This systematic review and meta-analysis evaluated the efficacy and safety of once-weekly basal insulin analogs compared with daily basal insulin analogs in adults with type 2 diabetes mellitus (T2DM) and included 14 randomized controlled trials (RCTs), comprising 8,487 subjects. RECENT FINDINGS: Evidence supports that once-weekly basal insulin analogs achieve comparable glycemic control to daily basal insulin analogs in adults with T2DM, offering greater reductions in HbA1c and improvements in time in range, with a safety profile similar to that of daily insulin regimens. In our analysis, once-weekly basal insulin resulted in a greater reduction in HbA1c compared with daily basal insulin (mean difference [MD] -0.09%, 95% CI -0.15 to -0.03), greater improvements in time in range (TIR) (MD 1.86%, 95% CI 0.73 to 2.98) and higher odds of attaining an HbA1c < 7.0% (OR 1.32, 95% CI 1.07 to 1.63, I2 64.9%). Rates of level 2 or 3 hypoglycemia did not differ significantly. Once-weekly basal insulin provides glycemic control comparable to daily basal insulin, with modest improvements in glycemic outcomes and similar hypoglycemia risk. Its primary advantage lies in treatment simplification and reduced injection burden, supporting its role as a convenient alternative to daily basal insulin in adults with T2DM.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.